ArticleMolecular imaging and biology2015
In vivo evaluation of inflammatory bowel disease with the aid of μPET and the translocator protein 18 kDa radioligand [18F]DPA-714.
Article in Molecular imaging and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Microglial Activation in Nociplastic Pain: From Preclinical Models to PET Neuroimaging and Implications for Targeted Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Translocator protein facilitates neutrophil-mediated mucosal inflammation in inflammatory bowel diseases.World journal of gastroenterology · 2025Article
- Imaging Agents for PET of Inflammatory Bowel Disease: A Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- PET assessment of acute gastrointestinal graft versus host disease.Bone marrow transplantation · 2023Review
- A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease.Journal of nanobiotechnology · 2022Article
- [Bone marrow transplantation · 2022Article
- Assessing organ-level immunoreactivity in a rat model of sepsis using TSPO PET imaging.Frontiers in immunology · 2022Article
- Mitochondrial translocator protein deficiency exacerbates pathology in acute experimental ulcerative colitis.Frontiers in physiology · 2022Article
- Toward Molecular Imaging of Intestinal Pathology.Inflammatory bowel diseases · 2020Review
- Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2020Article
- Article
- Development of a quantitative method for evaluating small intestinal motility using ultrasonography in mice.Experimental animals · 2019Article
- [EJNMMI research · 2018Article
- [ACS medicinal chemistry letters · 2018Article
- Evaluating [Molecular imaging and biology · 2017Article
- TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?Contrast media & molecular imaging · 2017Review
- The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory 'M1' human macrophages.PloS one · 2017Article
- Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.World journal of radiology · 2016Article
- Evaluation of PET Imaging Performance of the TSPO Radioligand [18F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation.Molecular imaging and biology · 2016Article
- Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging.Journal of neuroinflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the study was to validate [18F]DPA-714, a translocator protein (TSPO) 18 kDa radioligand, as a probe to non-invasively quantify the inflammatory state in inflammatory bowel disease (IBD) animal models. PROCEDURES: Quantitative positron emission tomography (PET) imaging of intestinal inflammation was conducted with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) a glucose metabolism surrogate marker and [18F]DPA-714 a ligand of the 18 kDa TSPO, on two IBD models. The first model was induced using dextran sodium sulfate (DSS), creating global inflammation in the colon. The second model was induced by rectally administering trinitrobenzenesulfonic acid (TNBS), creating local and acute inflammation.
resultsThe level of inflammation was analyzed using PET imaging on days 7 and 8. The analysis obtained with [18F]DPA-714, yielded a significant difference between the DSS treated (0.50 ± 0.17%ID/cc) and non-treated rats (0.35 ± 0.15%ID/cc). [18F]FDG on the other hand did not yield a significant difference. We did observe a mean glucose consumption in the colon increase from 0.40 ± 0.11 %ID/cc to 0.54 ± 0.17 %ID/cc. In the TNBS model, the uptake level of [18 F]DPA-714 increased significantly from 0.46 ± 0.23%ID/cc for the non-treated group, to 1.30 ± 0.62%ID/cc for those treated. PET signal was correlated with increased TSPO expression at cellular level.
conclusionsResults indicate that [18F]DPA-714 is suitable for studying inflammation in IBD models. [18F]DPA-714 could be a good molecular probe to non-invasively evaluate the level and localization of inflammation. Moreover, in vivo imaging using this TSPO ligand is potentially a powerful tool to stage and certainly to follow the evolution and therapeutic efficiency at molecular level within this disease family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.